

Supplementary Table 2. Comparison of changes of late osteoclast precursors

	Denosumab (N=11)	Zoledronate (N=12)	Total (N=23)	P-value ^{a)}
Baseline	0.10 (0.10-0.30)	0.20 (0.10-0.20)	0.20 (0.10-0.20)	0.750
Week 4	0.2 (0.10-0.40)	0.20 (0.10-0.20)	0.2 (0.10-0.25)	0.483
Change from baseline	0 (0-0.15)	0 (-0.10-0.07)	0 (-0.05-0.10)	0.641
%Change from baseline	0 (0-112.50)	0 (-50.0-75.0)	0 (-25.0-62.5)	0.589
P-value (baseline - week 4) ^{b)}	0.130	0.782	0.524	
Week 24	0.20 (0.05-0.30)	0.30 (0.13-0.60)	0.20 (0.10-0.50)	0.826
Change from baseline	0.10 (-0.20-0.15)	0.15 (0-0.47)	0.10 (0-0.30)	0.535
%Change from baseline	100 (-50-100)	100 (0-275)	100.0 (0-150.0)	0.154
P-value (baseline - week 24) ^{b)}	0.956	0.175	0.289	
Week 48	0.10 (0.10-0.15)	0.20 (0.20-0.30)	0.20 (0.10-0.25)	0.062
Change from baseline	0 (-0.20-0.05)	0 (0-0.10)	0 (-0.05-0.10)	0.069
%Change from baseline	0 (-62.5-50.0)	0 (0-87.5)	0 (-25.0-75.0)	0.138
P-value (week 0 - week 48) ^{b)}	0.802	0.243	0.622	

^{a)}P-values were derived from Student's *t*-test in analyzing between groups.

^{b)}P-values were derived from Wilcoxon signed-rank test in analyzing within groups.